ABSTRACT
Objective: To investigate the effect of acupressure therapy as an adjunctive therapy to pharmacological treatment on pain and health-related quality of life (QOL) among knee osteoarthritis (KOA) patients.Methods: One hundred KOA patients were recruited from the orthopedic out-patient clinic of the institute. The patients were allocated randomly (flipping-coin simple randomization method) into an intervention group (n=50) and a control group (n=50). Patients in the intervention group received acupressure therapy along with pharmacological treatment. Patients in the control group did not receive acupressure therapy but continued their pharmacological treatment. Changes in pain (visual analog scale, VAS) and QOL (short-form 36-item health survey, SF-36) scores at baseline (A0), during training session (A1), follow-up at the 3rd month after training (A2) and follow-up at the 6th month after training session (A3) were collected and examined. Multiple regression analysis was used to check the relationship between pain and SF-36 domains. Results: The VAS score of participants in the intervention group decreased at A3 (P=0.001). Scores of physical functioning (PF), role limitations due to emotional problems (RE) and mental health (MH) of SF-36 in the intervention group improved more as compared with the control group. Patients in the intervention group with improvement in VAS (pain) score showed greater changes in mean scores of all domains of SF-36 from baseline (all P?0.05). Except bodily pain (BP), the other domains of SF-36 were negatively correlated with pain score. Conclusion: Acupressure therapy with pharmacological treatment can improve health-related QOL and pain among KOA patients.
ABSTRACT
Thyroid malignant tumors are rarely associated with hyperfunctioning thyroid. The incidence of this co-incidence is highly variable. Here we report a rare case of papillary thyroid cancer associated with hyperthyroidism with brief literature review. 34 years-old female, presented with palpitation, excess sweating and weight loss for two months duration. There was asymmetrical swelling of the neck, more on left side which moves with deglutition. The result of histopathological examination confirmed papillary thyroid carcinoma. Literature review has showed an increasing number of papers reporting the association of high level of thyroid function tests and thyroid malignancy. Although the coexistence of them is rare, thyroid malignancy should be put in the differential diagnosis of hyperthyroid goiter and we can conclude that histopathology is the gold standard for the confirm diagnosis.
ABSTRACT
Primary cancer of the fallopian tube is very rare. An average of 20 to 30 new cases are reported each year. The incidence of this cancer varies from 0.14 to 1.8% of all Gynecological cancers. It is possible that the true incidence of PFTC has been underestimated because PFTC may have been mistakenly identified as ovarian tumors during initial surgery and/or during microscopic examination by a pathologist, as the histological appearance of these tumors are identical. Here in we report a classic case of PFTC in 40 year old female.
ABSTRACT
Background: Diabetes mellitus is a major public health problem with many complications. The Global Burden of Diabetes Study has projected that there will be a 122% increase in the number of people with diabetes mellitus worldwide in 2025 compared to 1995. Despite the availability of new agents for the treatment of type 2 diabetes mellitus oral sulfonylureas remain a cornerstone of therapy. Glibenclamide and glimepiride are widely used sulfonylurea antidiabetic drugs. Methods: A randomized, open, parallel group study was conducted by the Department of Pharmacology in association with Department of Medicine at Maharishi Markandeshwar Institute of Medical Sciences & Research (MMIMSR), Mullana, Ambala. Total 50 patients were divided into two groups I & II. In Group I (n=25) glibenclamide (5-15 mg/day) & in Group II (n=25) glimepiride (1-6mg/day) was administered for a period of 24 weeks and data analyzed by Student’s “t”- test. Results: There was a significant improvement in the post prandial blood sugar score (p<0.05) in both the study groups (I&II) after 24 weeks but post prandial blood level did not differ significantly (p>0.05) between the two groups. Conclusions: Both the drugs glibenclamide and glimepiride were effectively reduced post prandial blood sugar in both the groups. But these sulfonylurea drugs lowered post prandial blood sugar to a similar degree without significant difference between the two groups.
ABSTRACT
Background: Diabetes mellitus is a major public health problem. It is worldwide & a major risk factor for cardiovascular diseases. Glibenclamide and Glimepiride are widely used second generation sulfonylurea antidiabetic drugs. Both Glibenclamide and Glimepiride stimulate release of insulin from pancreatic acinar cells, by blocking an ATP-sensitive potassium channel. Therefore we evaluated the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin in patients of type II diabetes mellitus. Aims & Objective: (1) To find out the demographic profile of type II diabetes mellitus. (2) To find out the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin (HbA1c) in type II diabetes mellitus Patients. (3) To compare the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin (HbA1c) among the two study groups. Material and Methods: A prospective, randomized, open, parallel group study was carried out in patients attending OPD of Medicine department MM Institute of Medical Sciences and Research (MMIMSR), Mullana, Ambala. 50 patients were randomly assigned into groups A & group B. In Group A (n=25) Glibenclamide (5-15 mg/day) & in Group B (n=25) Glimepiride (1-6 mg/day) was administered for a period of 24 weeks. Data analyzed by Student’s “t”- test. Results: It was found that prevalence of type II diabetes mellitus is more common among the male patients There was a significant reduction in glycosylated haemoglobin score (p<0.05) in both the study groups after 24 weeks but glycosylated haemoglobin level did not differ significantly (p>0.05) between the two groups. Conclusion: Glibenclamide and Glimepiride lowered glycosylated haemoglobin to a similar degree without significant difference between the two groups.